Advertisement

Topics

Celgene gets FDA breakthrough therapy designation for Pomalyst to treat Kaposi sarcoma

03:27 EDT 14 May 2019 | Pharmaceutical Business Review

The designation has been granted for Pomalyst to treat patients with HIV-positive Kaposi sarcoma who have previously received systemic chemotherapy, in addition to patients with HIV‐negative Kaposi’s sarcoma.

The post Celgene gets FDA breakthrough therapy designation for Pomalyst to treat Kaposi sarcoma appeared first on Pharmaceutical Business review.

Original Article: Celgene gets FDA breakthrough therapy designation for Pomalyst to treat Kaposi sarcoma

NEXT ARTICLE

More From BioPortfolio on "Celgene gets FDA breakthrough therapy designation for Pomalyst to treat Kaposi sarcoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Human Immuno Deficiency Virus (HIV)
Human Immunodeficiency Virus (HIV), the causative agent of AIDS. The Human Immunodeficiency Virus, more commonly known as HIV, is a member of the lentivirus sub-set of the retrovirus family of pathogens. It causes AIDS, or Acquired Immuno Deficiency Sy...